Synovial Proliferation: How Cell Overgrowth Damages Joints

Synovial proliferation is the abnormal overgrowth of the tissue that lines your joints, transforming a membrane normally just one cell thick into a thickened, aggressive mass that can invade and destroy cartilage and bone. It is the hallmark of rheumatoid arthritis, but it also shows up in osteoarthritis, bleeding disorders, childhood joint diseases, infections, and even tumors. The process involves far more than simple cell multiplication: inflamed synovial cells rewire their metabolism, recruit new blood vessels, and produce enzymes that eat away at the structures they were designed to protect.

What the Synovium Normally Does

A healthy synovial membrane is thin and unassuming. It consists of a lining layer, usually just one or two cells deep, that sits on top of looser connective tissue containing blood vessels and nerves. The lining contains two main cell types: macrophage-like cells that clear debris from the joint cavity, and fibroblast-like cells that produce lubricating fluid and maintain the surrounding matrix. Together they regulate what moves in and out of the joint space, keeping the cartilage nourished and the joint moving smoothly.

In healthy tissue, these lining cells share some characteristics with the cells that line organs and body surfaces. They express proteins associated with structured, orderly tissue, including E-cadherin and type IV collagen, which help maintain the membrane’s organized single-layer architecture.¹ When disease sets in, this orderly structure breaks down dramatically.

How Synovial Cells Turn Aggressive

In rheumatoid arthritis, the fibroblast-like cells of the synovium undergo a lasting personality change. They start expressing markers associated with scar-forming tissue, including a protein called alpha-smooth muscle actin that healthy synovial cells do not produce.² This shift resembles a process seen in wound healing and cancer, where organized surface cells transform into mobile, tissue-invading cells. Once they acquire this new identity, rheumatoid fibroblast-like synoviocytes develop what researchers describe as a uniquely aggressive phenotype, becoming capable of burrowing into the cartilage and bone matrix surrounding the joint.³

These changes are stable, meaning the cells retain their aggressive behavior even when removed from the inflamed joint and grown in a laboratory dish. That persistence is part of what makes rheumatoid arthritis so difficult to reverse once established. The cells are not just responding to inflammation; they have been permanently reprogrammed by it.

The Inflammatory Signals That Drive It

Synovial proliferation does not happen in a vacuum. It is fueled by a cocktail of inflammatory signaling molecules. Three cytokines play leading roles: TNF-alpha, interleukin-6, and interleukin-1-beta. During active rheumatoid arthritis, these molecules activate both macrophages and fibroblast-like synoviocytes, promoting further inflammation and also triggering the bone-destroying cells called osteoclasts.⁴ The result is a self-reinforcing loop: inflamed synovial cells produce cytokines, which attract more immune cells, which produce more cytokines, which stimulate more synovial growth.

Smaller regulatory molecules called microRNAs also play a role in keeping synovial cells in their aggressive state. These tiny RNA fragments influence which genes get turned on or off in the fibroblast-like synoviocytes, and specific patterns of microRNA activity have been linked to the establishment and maintenance of the disease.⁵ This adds a layer beyond simple inflammation: even after the initial trigger fades, these gene-regulatory changes can keep the proliferative program running.

Oxygen Starvation and New Blood Vessels

As the synovium thickens, the tissue outgrows its blood supply, creating pockets of low oxygen. Paradoxically, this oxygen starvation makes things worse. Hypoxic conditions push fibroblast-like synoviocytes to ramp up production of vascular endothelial growth factor (VEGF), a protein that stimulates the formation of new blood vessels.⁶ Low oxygen also increases the overall drive toward new vessel formation in rheumatoid synovial cells, as demonstrated in laboratory models showing enhanced blood vessel growth under hypoxic conditions.⁷

These new blood vessels are not just passive supply lines. They ferry in more immune cells, further stoking the inflammatory fire. Research using animal models has shown that under hypoxic conditions, the altered fibroblast-like synoviocytes alone are sufficient to recruit inflammatory cells and promote new vessel growth, both of which perpetuate the chronic inflammation.⁸ The acid environment that accompanies this low-oxygen state also shifts synovial cell metabolism toward rapid energy production, which in turn promotes further proliferation.⁹

Pannus and Joint Destruction

When proliferating synovium becomes thick and invasive enough, it earns a specific name: pannus. This mass of inflamed tissue creeps across the cartilage surface, anchoring itself and releasing enzymes that break down the structural proteins holding cartilage together. Rheumatoid arthritis is characterized by persistent synovitis and the formation of pannus, which ultimately destroys cartilage, the underlying bone, and surrounding soft tissues.¹⁰

Among the enzymes doing the most damage is MMP-3, a matrix metalloproteinase that chews through the proteoglycan-rich cartilage matrix. MMP-3 is found at high levels in pannus tissue, and its production is further boosted by interleukin-1-beta, suggesting a direct link between the inflammatory cytokine environment and the physical erosion of cartilage.¹¹ For patients, this is where the disease moves from painful swelling to lasting structural damage: joint narrowing, erosions visible on X-rays, and eventually the kind of deformity that can require joint replacement.

Synovial Proliferation Beyond Rheumatoid Arthritis

Rheumatoid arthritis gets most of the attention, but synovial proliferation is not exclusive to it. The synovium reacts to many kinds of joint insult, and the degree of reaction varies widely by condition.

Osteoarthritis

For decades, osteoarthritis was thought of as a purely mechanical “wear and tear” disease with minimal inflammation. That view has changed. Synovitis is now recognized as a common feature of osteoarthritis, though it tends to be milder than what you see in rheumatoid disease. When researchers scored synovial inflammation on a standardized scale, osteoarthritis consistently scored lower than rheumatic conditions: a median score of 2 for osteoarthritis compared with 5 for rheumatoid arthritis, with high-grade synovitis strongly linked to rheumatic rather than degenerative disease.¹² Still, even low-grade synovial inflammation in osteoarthritis correlates with symptoms and disease progression, which is why imaging of synovitis in osteoarthritis has become an active area of research.¹³

Hemophilic Arthropathy

In people with hemophilia, repeated bleeding into joints triggers its own form of synovial proliferation. Even subclinical bleeds, ones too small to cause obvious swelling, can set off a cycle of blood-induced synovitis that leads to joint remodeling, chronic pain, and eventually the need for joint replacement.¹⁴ Iron from degraded blood cells is thought to be a major irritant, stimulating the synovial lining to thicken and become chronically inflamed. Because no specific treatment exists to reverse blood-induced synovitis once it is established, preventing bleeds through clotting factor replacement remains the cornerstone of joint health in hemophilia.

Post-Infectious Arthritis

Synovial proliferation can also persist after an infection has been cleared. In Lyme arthritis, some patients develop ongoing joint inflammation even after the bacteria have been killed by antibiotics. Analysis of these joints shows microRNA patterns reflecting chronic inflammation, synovial proliferation, and a breakdown of normal tissue repair, a profile quite different from what is seen during active infection.¹⁵ The description of “tumor-like proliferative responses” in these joints underscores just how aggressive synovial overgrowth can become even without the original infection driving it.

Juvenile Idiopathic Arthritis

Children face a unique complication from synovial proliferation. In juvenile idiopathic arthritis (JIA), the inflamed synovial fibroblasts take on characteristics normally seen in bone-forming cartilage cells. They produce bone-related enzymes and can influence nearby cartilage cells to become highly proliferative, potentially contributing to the bony overgrowth and limb-length differences seen in affected children.¹⁶ Research suggests these synovial cells create a local environment favorable for abnormal bone formation, which could explain the growth disturbances that distinguish childhood arthritis from the adult form.¹⁷

Synovial Tumors and Pigmented Villonodular Synovitis

Sometimes synovial proliferation crosses the line from inflammatory to neoplastic. Tenosynovial giant cell tumor (TGCT) and its diffuse form, historically called pigmented villonodular synovitis (PVNS), represent conditions where synovial cells become clonal, meaning they arise from a single genetically altered ancestor cell. In most cases, a chromosomal rearrangement involving a gene called CSF1 is the culprit. This translocation causes overexpression of CSF1, a growth factor that recruits large numbers of macrophages and other inflammatory cells into the joint lining.¹⁸

What makes TGCT unusual among tumors is that only a minority of the cells in the mass carry the genetic translocation. The neoplastic cells closely resemble normal synoviocytes and use CSF1 signaling to recruit a much larger population of non-neoplastic inflammatory cells around them, creating a “landscape effect” that produces the bulk of the tumor mass.¹⁹ For patients, TGCT typically presents as persistent swelling in a single joint, most often the knee, and can cause significant pain, stiffness, and joint destruction if left untreated.

How Synovial Proliferation Is Detected

You cannot see synovial thickening from the outside of a joint, and blood tests alone do not tell the full story. Imaging plays a central role. MRI is generally considered the gold standard: it can distinguish between synovial thickening and simple fluid accumulation in the joint, especially when a contrast agent is used. In one study of rheumatoid shoulder joints, MRI detected synovitis in over 90% of patients, while standard ultrasound could identify abnormal patterns but struggled to tell whether those patterns represented fluid or actual synovial overgrowth.²⁰ Power Doppler ultrasound, which picks up blood flow signals within thickened synovium, can improve specificity, especially with contrast enhancement, though it still missed synovitis in a substantial proportion of patients in that same study.

Blood-based biomarkers are an emerging complement to imaging. Researchers have identified markers that reflect the breakdown of synovial tissue by matrix metalloproteinases, the same enzymes involved in joint destruction.²¹ One particularly promising marker measures specific fragments of type III and type IV collagen released when metalloproteinases chew through synovial tissue. In a large group of patients with early arthritis followed for five years, higher levels of this marker in the blood were strongly associated with greater risk of X-ray-visible joint damage over time, independent of other known risk factors.²² A simple blood test that flags synovial destruction before it shows up on imaging would be a significant advance, though these markers are not yet in routine clinical use.

Treating the Overgrowth

Treatment depends on the underlying cause and the severity of the proliferation. For inflammatory conditions like rheumatoid arthritis, biologic therapies that block specific cytokines have changed the landscape. When these treatments work, one of the most consistent tissue-level changes is a drop in the number of macrophages in the deeper layer of the synovium. That reduction in macrophage infiltration tracks closely with clinical improvement measured by standard disease activity scores, making sublining macrophage counts a reliable tissue marker of treatment response across different drug classes.²³

When medication alone does not control synovial overgrowth, surgical removal of the inflamed synovium, a procedure called synovectomy, is an option. It can be done as open surgery or arthroscopically. A retrospective analysis of knee synovectomy followed by radiosynoviorthesis (injection of a radioactive substance to mop up residual synovial tissue) found recurrence-free survival of roughly 84% at two years and about 62% at ten years, though results varied by condition: patients with PVNS had the highest recurrence rates, while those with peripheral spondyloarthritis fared the best.²⁴ For hemophilia patients with persistent elbow synovitis, radiosynovectomy alone is often preferred as a first-line approach, with surgical synovectomy reserved for cases where three consecutive radiosynovectomies at six-month intervals fail to control the problem.²⁵

Targeted Drugs for Synovial Tumors

The understanding that TGCT is driven by CSF1 overexpression opened the door to a genuinely targeted treatment. Pexidartinib, a drug that blocks the receptor for CSF1, was the first systemic therapy approved for this condition. In the randomized phase 3 trial, about 39% of patients on pexidartinib showed a measurable tumor response at 25 weeks, compared with 0% on placebo, and none of the responders had progressed at the six-month follow-up point.²⁶ Individual case reports have documented even more striking results, with one patient showing a 48% reduction in tumor volume after four months and sustained disease stability for over four years on continued treatment.²⁷

Pexidartinib is not the only option in this class. Vimseltinib is also now approved in the United States for TGCT, and additional CSF1 receptor inhibitors are in clinical development.²⁸ For patients who previously faced the choice between repeated surgeries with high morbidity and living with a progressively destructive joint mass, these drugs represent a real shift in what is possible.

When Joint Mechanics Change

Synovial proliferation does not only destroy tissue over the long term; it alters how a joint functions mechanically in the short term as well. Studies in animal models with joint inflammation have measured significantly elevated pressure inside affected joints compared with healthy ones. Joints with synovitis and capsulitis had the highest pressures, but even joints with primary synovitis alone showed meaningfully elevated intra-articular pressure. As synovitis progressed to involve the joint capsule, the soft tissues surrounding the joint became stiffer, and the range of motion during flexion decreased.²⁹ While these data come from veterinary research on racehorses rather than human joints, the basic mechanical principles translate: a thickened, swollen synovium takes up space, raises pressure, stiffens the capsule, and restricts movement. For patients, this often manifests as morning stiffness that eases with activity, a sensation of fullness in the joint, and a gradual loss of the ability to fully bend or straighten the affected joint.

This mechanical dimension matters for treatment decisions. Reducing inflammation and synovial bulk early, before the capsule and surrounding structures stiffen permanently, preserves more function. Once fibrosis sets in and the architecture of the soft tissues is remodeled, even complete resolution of the synovial inflammation may not restore full range of motion.